Drug Profile
MP 1032
Alternative Names: MP-1032Latest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator MetrioPharm
- Class Amines; Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ketones; Phthalazines; Small molecules; Sodium compounds
- Mechanism of Action Free radical scavengers; Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections; Plaque psoriasis
- Phase I Duchenne muscular dystrophy; Inflammatory bowel diseases; Juvenile rheumatoid arthritis; Multiple sclerosis; Rheumatoid arthritis
- Preclinical Chronic obstructive pulmonary disease
- No development reported Neurodegenerative disorders
Most Recent Events
- 31 Jan 2024 Efficacy data from a phase IIa trial in COVID-2019 infections released by MetrioPharm
- 28 Nov 2023 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Switzerland (PO)
- 25 Oct 2023 MP 1032 receives rare paediatric disease designation (RPDD) for Duchenne muscular dystrophy in USA